It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
HOME > BUSINESS
BUSINESS
- Sawai Recalls GI Drug after Doping Substance Found
March 6, 2019
- Fujifilm, Tokyo Medical and Dental Univ. Ink Regenerative Medicine Pact for Meniscal Injury
March 6, 2019
- Osteoporosis Drug Evenity Now Available: Amgen Astellas
March 5, 2019
- ASKA to Relocate Kawasaki Research Center to Shonan iPark; 1st Non-Takeda Pharma Tenant
March 5, 2019
- Teijin Pharma’s Feburic Now Available in China
March 5, 2019
- Sumitomo Dainippon to Bolster Functions in Singapore Subsidiary; Maximizing South East Asian Biz
March 5, 2019
- Pfizer Japan Rolls Out EGFR Inhibitor Vizimpro
March 4, 2019
- Kyowa Kirin Resubmits Istradefylline for US Approval for 1st time in 12 Years, Based on Japanese Data
March 4, 2019
- Nichi-Iko Scoops Up FDA-Approved Manufacturing Plant in US from Danish Pharma
March 4, 2019
- Shionogi Strikes Malaria Pact with Nagasaki University
March 1, 2019
- Kaken Grabs Japan Rights to Arbor’s Head Lice Drug
March 1, 2019
- Taisho to Snap Up More Shares in Vietnam’s DHG, Boost Southeast Asian Biz
March 1, 2019
- More Pharmacies Turning to Medical System Network’s Price Negotiation Service after Distribution Guidelines Introduced
March 1, 2019
- JCR’s Hunter Syndrome Drug Earns Orphan Status in Europe
March 1, 2019
- Mitsubishi Tanabe, Servier Tie Up on Tenelia Promotion in China
March 1, 2019
- EMA Accepts Astellas’ AML Drug Xospata for Review, Approval Could Come This Summer
March 1, 2019
- Takeda, Aflac, 6 Other Firms to Develop Insurance with Healthy Living Rewards in 1st Shonan Initiative
February 28, 2019
- Pfizer Transferring MA/Distribution Rights for 3 Off-Patent Brands to Teikoku Seiyaku
February 28, 2019
- Ono Files Parkinson’s Drug Opicapone in Japan
February 28, 2019
- Eisai to Fund Japan NGO for Prevention of Infectious Diseases in Sudan
February 28, 2019
ページ
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…